myBCW

What's New at BloodCenter of Wisconsin Diagnostic Laboratories

Red Blood Cell Genotyping

BloodCenter of Wisconsin's Diagnostic Labs are your full spectrum partner in Red Cell Genotyping, offering Prenatal Diagnostics, Donor Screening, and now Patient Panels.  BloodCenter of Wisconsin can provide results faster and more cost effectively.  But more importantly, we provide you confidence in your results and patient care.

 

 

Rh D Discrepancy Analysis

The Rh D polypeptide is a highly immunogenic protien present on the red cell surface of approximately 85% of Caucasians, >90% of Africans and nearly 100% of Asians.  Some of the more than 200 RHD alleles lead to a reduced or variable expression of the D antigenic epitopes on the red cell surface.  Patients with these abberant alleles may be mistyped by serology.  It is important to resolve these discrepancies to determine appropriate anti-D prophylaxis for pregnant women and the Rh status for trasfusion recipients at risk of making anti-D.

 

BloodCenter of Wisconsin's new service, Rh D Discrepancy Analysis, tests samples using 4 FDA licensed antisera.  If a discrepancy is suspected, testing can reflex to molecular genotyping to give a comprehensive assessment of an individual's Rh D status.

 

 

Neutrophil Antigen Genotyping

DNA-based testing is now available for 4 neutrophil alloantigen systems:  HNA-1a/1b/1c, HNA-3a/3b, HNA-4a/4b and HNA-5a/5b.  Serologic typing methods are cumbersome, time consuming, and require fresh neutrophils.  Further, serologic methods depend on the availability of well-characterized typing sera which are not available for HNA-4 or HNA-5.  DNA-based typing methods overcome these concerns.

 

BloodCenter of Wisconsin's Neutrophil Antigen Genotyping has many applications, including:

  • Confirming antibody specificity in patient samples
  • Predicting through parental genotyping the probability of future infants being affected by NAN, and
  • Determining those blood donors at risk of producing HNA-3 antibodies to serve as aTRALI risk reduction practice

 

AML and MPN Testing, Diagnosis, and Consultation

Acute myeloid leukemia (AML) is the most common type of leukemia, with an estimated 13,000 new cases diagnosed in the United States annually. Diagnostic Laboratories’ new AML panel includes novel prognostic markers to better help patient outcomes.

 

Myeloproliferative neoplasms (MPNs) are a group of diseases that affect blood cell formation. Classic MPNs include:

  • Polycythemia vera (PV)
  • Essential thrombocythemia (ET)
  • Primary myelofibrosis (PMF)

Diagnostic Lab’s MPN testing algorithm uses an integrated suite of molecular tests that detect three markers directly associated with MPNs.

 

 

Hemostasis, Thrombosis, & Platelet Immune Disorders

Expanded Menu to Support Diagnosis of TTP

Thrombotic thrombocytopenic purpura, or TTP, is a rare disease in which small blood clots form in blood vessels throughout the body. TTP is caused by lack of the enzyme ADAMTS13.

 

Low levels of ADAMTS13 in patients with acquired TTP appear to be caused by the presence of circulating anitbodies to ADAMTS13. In the laboratory, about 80% of these antibodies inhibit activity of ADAMTS13. Laboratory tests for these inhibitory antibodies cannot detect the remaining 20% of clinically important antibodies. BloodCenter of Wisconsin's new test, ADAMTS13 Antibody, will detect nearly all of the remaining antibodies.

 

Disease causing mutations have been identified throughout the coding sequence of the ADAMTS13 gene including missense, nonsense and splice site alterations, as well as necleotide deletions and insertions.  BloodCenter of Wisconsin's ADAMTS13 Sequence Analysis with mutation detection will confirm a diagnosis of congenital ADAMTS13 deficiency and can be useful in the evaluation of family members of patients with known ADAMTS13 mutations.

 

 

Molecular Hematology & Oncology

KIT Exons 8 and 17 Mutation Analysis

Core binding factor acute myeloid leukemia (AML) comprises ~20% of AML cases. Patients tend to have a favorable prognosis, but half of all patients will relapse in 5 years. KIT mutations in exons 8 and 17 are associated with a higher rate of relapse.

 

KIT Exons 8 and 17 Mutation Analysis, a new molecular assay from BloodCenter of Wisconsin, allows physicians to assess risk and appropriately select therapy.

 

CEBPA Mutation Analysis
Mutations in CEBPA are found in ~15% of patients with Acute Myeloid Leukemia (AML). CEBPA mutations are associated with a relatively favorable prognosis. CEBPA mutations also define an extremely rare form of inherited AML.

  

 

Contact Us
For additional information, please contact our Client Services team at (800) 245-3117, ext. 6250, or email LabInfo@bcw.edu.
 

 
 
Manage Your Site(manage site)
Site Hierarchy
You have chosen the  section.
Add a new sub-section to this section of your site.
Remove this section from your site.
Move this section to another location in your site.
Use this section as the error handler for your site.
Do not use this section as the error handler for your site.
Edit the properties of this section below...
Section ID:
Section Label:
Include in Navigation:
Contributor Only:
Url Directory Name:
Url Page Name:
Maximum Age:
You have chosen the  section.
  Primary layout page is not set    clear
Preview layout   Apply
You have chosen the  section.
  Secondary layout page is not set    clear
Preview layout   Apply
You have chosen the  section.
Edit the custom properties of this section below...